JP7536272B2 - インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 - Google Patents

インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 Download PDF

Info

Publication number
JP7536272B2
JP7536272B2 JP2018543209A JP2018543209A JP7536272B2 JP 7536272 B2 JP7536272 B2 JP 7536272B2 JP 2018543209 A JP2018543209 A JP 2018543209A JP 2018543209 A JP2018543209 A JP 2018543209A JP 7536272 B2 JP7536272 B2 JP 7536272B2
Authority
JP
Japan
Prior art keywords
seq
oligonucleotide
psl2
virus
vrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018543209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511471A5 (https=
JP2019511471A (ja
Inventor
ジェフリー エス． グレン，
レイチェル ハーゲイ，
エドワード パム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2019511471A publication Critical patent/JP2019511471A/ja
Publication of JP2019511471A5 publication Critical patent/JP2019511471A5/ja
Priority to JP2022162516A priority Critical patent/JP2022176378A/ja
Application granted granted Critical
Publication of JP7536272B2 publication Critical patent/JP7536272B2/ja
Priority to JP2025061328A priority patent/JP2025096365A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018543209A 2016-03-02 2017-03-01 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 Active JP7536272B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022162516A JP2022176378A (ja) 2016-03-02 2022-10-07 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
JP2025061328A JP2025096365A (ja) 2016-03-02 2025-04-02 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302548P 2016-03-02 2016-03-02
US62/302,548 2016-03-02
PCT/US2017/020241 WO2017151795A1 (en) 2016-03-02 2017-03-01 Pan-genotypic agents against influenza virus and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162516A Division JP2022176378A (ja) 2016-03-02 2022-10-07 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019511471A JP2019511471A (ja) 2019-04-25
JP2019511471A5 JP2019511471A5 (https=) 2020-03-19
JP7536272B2 true JP7536272B2 (ja) 2024-08-20

Family

ID=59743201

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543209A Active JP7536272B2 (ja) 2016-03-02 2017-03-01 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
JP2022162516A Withdrawn JP2022176378A (ja) 2016-03-02 2022-10-07 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
JP2025061328A Pending JP2025096365A (ja) 2016-03-02 2025-04-02 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022162516A Withdrawn JP2022176378A (ja) 2016-03-02 2022-10-07 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
JP2025061328A Pending JP2025096365A (ja) 2016-03-02 2025-04-02 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法

Country Status (17)

Country Link
US (1) US10597658B2 (https=)
EP (3) EP3800257B1 (https=)
JP (3) JP7536272B2 (https=)
CN (1) CN108778344A (https=)
CA (1) CA3014776A1 (https=)
DK (1) DK3800257T3 (https=)
ES (1) ES2981765T3 (https=)
FI (1) FI3800257T3 (https=)
HR (1) HRP20240765T1 (https=)
HU (1) HUE066977T2 (https=)
LT (1) LT3800257T (https=)
PL (1) PL3800257T3 (https=)
PT (1) PT3800257T (https=)
RS (1) RS65707B1 (https=)
SI (1) SI3800257T1 (https=)
SM (1) SMT202400253T1 (https=)
WO (1) WO2017151795A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148747A1 (en) 2004-10-26 2006-07-06 Stein David A Antisense antiviral compound and method for treating influenza viral infection
US20120003156A1 (en) 2008-07-01 2012-01-05 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
JP2012506698A (ja) 2008-10-27 2012-03-22 アカデミシュ ジーケンハウス ライデン ヒトＤｕｃｈｅｎｎｅ型筋ジストロフィー遺伝子のエクソン４３、４６、５０〜５３のうちの少なくとも１個の効率的なスキッピングのための方法及び手段
JP2013510584A (ja) 2009-11-13 2013-03-28 サレプタ セラピューティクス， インコーポレイテッド アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法
JP2013515504A (ja) 2009-12-29 2013-05-09 カッパーアールエヌエー，インコーポレイテッド 核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
JP2013532965A (ja) 2010-06-01 2013-08-22 エータイアー ファーマ， インコーポレイテッド リジルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT69956A (en) * 1990-08-14 1995-09-28 Isis Pharmaceuticals Inc Methode for inhibition of influenza virus by antiseuse oligonucleotides
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
AU2006235364A1 (en) * 2005-04-08 2006-10-19 Marina Biotech, Inc. RNAi therapeutic for respiratory virus infection
EP1937066A4 (en) * 2005-08-18 2008-12-24 Alnylam Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES
WO2007084359A2 (en) * 2006-01-17 2007-07-26 Oligos Etc., Inc. Compositions and methods for the treatment of influenza infection
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
CA2666657A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20090042823A1 (en) 2007-08-10 2009-02-12 Mdrna, Inc. Uses of broad spectrum rnai therapeutics against influenza

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148747A1 (en) 2004-10-26 2006-07-06 Stein David A Antisense antiviral compound and method for treating influenza viral infection
US20120003156A1 (en) 2008-07-01 2012-01-05 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
JP2012506698A (ja) 2008-10-27 2012-03-22 アカデミシュ ジーケンハウス ライデン ヒトＤｕｃｈｅｎｎｅ型筋ジストロフィー遺伝子のエクソン４３、４６、５０〜５３のうちの少なくとも１個の効率的なスキッピングのための方法及び手段
JP2013510584A (ja) 2009-11-13 2013-03-28 サレプタ セラピューティクス， インコーポレイテッド アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法
JP2013515504A (ja) 2009-12-29 2013-05-09 カッパーアールエヌエー，インコーポレイテッド 核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
JP2013532965A (ja) 2010-06-01 2013-08-22 エータイアー ファーマ， インコーポレイテッド リジルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ａｎｔｉｖｉｒａｌ Ｒｅｓ．，２０１１，Ｖｏｌ．９２，ｐｐ．６４－７２
Ａｒｃｈ．Ｖｉｒｏｌ．，２００９，Ｖｏｌ．１５４，ｐｐ．８２１－８３２
Ｊ．Ｇｅｎｅ Ｍｅｄ．，２０１１，Ｖｏｌ．１３，ｐｐ．２４３－２４９
Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｓｙｍｐｏｓｉｕｍ Ｓｅｒｉｅｓ Ｎｏ．５３，２００９，ｐｐ．２８５－２８６

Also Published As

Publication number Publication date
PL3800257T3 (pl) 2024-09-16
DK3800257T3 (da) 2024-06-24
HRP20240765T1 (hr) 2024-09-13
EP3423107A4 (en) 2020-01-15
JP2025096365A (ja) 2025-06-26
SMT202400253T1 (it) 2024-09-16
RS65707B1 (sr) 2024-08-30
US10597658B2 (en) 2020-03-24
JP2022176378A (ja) 2022-11-25
WO2017151795A1 (en) 2017-09-08
EP3800257A1 (en) 2021-04-07
EP4389221A3 (en) 2024-11-20
LT3800257T (lt) 2024-07-25
HUE066977T2 (hu) 2024-09-28
JP2019511471A (ja) 2019-04-25
EP4389221A2 (en) 2024-06-26
CA3014776A1 (en) 2017-09-08
US20190136242A1 (en) 2019-05-09
ES2981765T3 (es) 2024-10-10
EP3423107A1 (en) 2019-01-09
PT3800257T (pt) 2024-06-26
EP3800257B1 (en) 2024-05-01
FI3800257T3 (fi) 2024-06-19
SI3800257T1 (sl) 2025-04-30
CN108778344A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
Hutchinson et al. Genome packaging in influenza A virus
JP2025096365A (ja) インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
Steinhauer et al. Genetics of influenza viruses
Szabat et al. RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication
WO2021201996A1 (en) Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
US12618063B2 (en) Pan-genotypic agents against influenza virus and methods of using the same
US20240425852A1 (en) Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same
Motard et al. A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease
HK40113249A (en) Pan-genotypic agents against influenza virus and methods of using the same
Giannecchini et al. Packaging signals in the 5′-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules
Giannecchini et al. Oligonucleotides derived from the packaging signal at the 5′ end of the viral PB2 segment specifically inhibit influenza virus in vitro
EP4464779A2 (en) Pan-genotypic agents against respiratory viruses and methods of using the same
Crescenzo-Chaigne et al. The Panhandle formed by influenza A and C virus NS non-coding regions determines NS segment expression
US10383935B2 (en) Methods of making and using live attenuated viruses
HK40118855A (en) Pan-genotypic agents against respiratory viruses and methods of using the same
AU2024341512A1 (en) Agents against respiratory viruses and methods of using the same
HK40091735A (zh) 抗呼吸道病毒的泛基因型药剂及其使用方法
HK1262033A1 (en) Pan-genotypic agents against influenza virus and methods of using the same
Hagey et al. Identification and targeting of a pan-genotypic influenza A virus RNA structure that mediates packaging and disease
Winn The role of host factor Transportins in Influenza virus entry and infection
US11046958B2 (en) Antisense oligonucleotides that inhibit influenza virus replication and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221007

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221121

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221228

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240731

R150 Certificate of patent or registration of utility model

Ref document number: 7536272

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150